Bispecific antibodies and targeted cellular cytotoxicity
- PMID: 1676265
- DOI: 10.1016/0167-5699(91)90156-N
Bispecific antibodies and targeted cellular cytotoxicity
Abstract
The Second International Conference on Bispecific Antibodies (BsAbs) and Targeted Cellular Cytotoxicity considered how targeted cytotoxicity can be used (1) to increase understanding of the general mechanisms of cellular cytotoxicity and (2) clinically in the treatment of cancer and infectious disease. BsAbs, the main mediators of targeted cellular cytotoxicity, can be made by chemical crosslinking, by fusing hybridoma cells and by molecular genetic approaches. BsAbs bind to target cells via one V region and trigger molecules such as T-cell receptors (TCRs) or FcR for IgG (Fc gamma R) on cytotoxic cells via their other V region. This linking of triggering structures to target cells induces target cell lysis and provides important clues to the signals used to elicit the lytic process.
Similar articles
-
Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).J Hematother. 1992 Spring;1(1):85-94. doi: 10.1089/scd.1.1992.1.85. J Hematother. 1992. PMID: 1365020 Clinical Trial.
-
Bispecific antibody therapy of two murine B-cell lymphomas.Int J Cancer Suppl. 1992;7:67-8. Int J Cancer Suppl. 1992. PMID: 1428409
-
Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.J Immunol. 1987 Nov 15;139(10):3536-41. J Immunol. 1987. PMID: 2960735
-
Bispecific antibodies.Crit Rev Immunol. 1992;12(3-4):101-24. Crit Rev Immunol. 1992. PMID: 1476620 Review.
-
Alternative triggering molecules and single chain bispecific antibodies.J Hematother. 1995 Oct;4(5):377-82. doi: 10.1089/scd.1.1995.4.377. J Hematother. 1995. PMID: 8581372 Review.
Cited by
-
Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.J Exp Med. 1992 Jan 1;175(1):217-25. doi: 10.1084/jem.175.1.217. J Exp Med. 1992. PMID: 1346155 Free PMC article.
-
Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).Clin Exp Immunol. 1992 Dec;90(3):368-75. doi: 10.1111/j.1365-2249.1992.tb05853.x. Clin Exp Immunol. 1992. PMID: 1281055 Free PMC article.
-
Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes.Clin Exp Immunol. 1992 Aug;89(2):310-4. doi: 10.1111/j.1365-2249.1992.tb06951.x. Clin Exp Immunol. 1992. PMID: 1386300 Free PMC article.
-
Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody.Jpn J Cancer Res. 1992 Jul;83(7):761-8. doi: 10.1111/j.1349-7006.1992.tb01977.x. Jpn J Cancer Res. 1992. PMID: 1517150 Free PMC article.
-
Expression of tumor-associated glycoantigen, sialyl Lewis(a), in human head and neck squamous cell carcinoma and its application to tumor immunotherapy.Jpn J Cancer Res. 1994 Sep;85(9):887-91. doi: 10.1111/j.1349-7006.1994.tb02964.x. Jpn J Cancer Res. 1994. PMID: 7961115 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources